Novartis | NOVN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Alcon AG USD 1.69B 175M 2026-03
Almirall EUR 429.87M 180.02M 2025-12
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
Autolus Therapeutics Ltd USD 1.65M 2.69M 2026-03
Bayer EUR 6.94B 1.58B 2025-12
Biogen USD 1.82B 169.5M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Fresenius EUR 1.51B 214M 2025-12
Fresenius Medical Care EUR 1.18B 210M 2026-03
Genmab DKK 977M 13M 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
GRIFOLS EUR 686.84M 56.95M 2025-12
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
J&J USD 17.24B 642M 2026-03
Lakefront Biotherapeutics EUR 1.68M 898.68M 2026-03
Lonza CHF 1.29B 248M 2025-06
Merck EUR 3.07B 104M 2026-03
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Novartis USD 10.82B 694M 2025-09
Novo Nordisk DKK 64.01B 1.19B 2025-06
Orion EUR 254M 254.7M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Philips EUR 1.77B 522M 2026-03
Recordati EUR 472.65M 40.24M 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
UCB EUR 3.19B 621M 2025-12